Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. / Knorr, Ulla; Simonsen, Anja Hviid; Jensen, Camilla Steen; Zetterberg, Henrik; Blennow, Kaj; Akhøj, Morten; Forman, Julie; Hasselbalch, Steen Gregers; Kessing, Lars Vedel.

In: Journal of Affective Disorders, Vol. 297, 2022, p. 623-633.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Knorr, U, Simonsen, AH, Jensen, CS, Zetterberg, H, Blennow, K, Akhøj, M, Forman, J, Hasselbalch, SG & Kessing, LV 2022, 'Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study', Journal of Affective Disorders, vol. 297, pp. 623-633. https://doi.org/10.1016/j.jad.2021.10.074

APA

Knorr, U., Simonsen, A. H., Jensen, C. S., Zetterberg, H., Blennow, K., Akhøj, M., Forman, J., Hasselbalch, S. G., & Kessing, L. V. (2022). Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. Journal of Affective Disorders, 297, 623-633. https://doi.org/10.1016/j.jad.2021.10.074

Vancouver

Knorr U, Simonsen AH, Jensen CS, Zetterberg H, Blennow K, Akhøj M et al. Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. Journal of Affective Disorders. 2022;297:623-633. https://doi.org/10.1016/j.jad.2021.10.074

Author

Knorr, Ulla ; Simonsen, Anja Hviid ; Jensen, Camilla Steen ; Zetterberg, Henrik ; Blennow, Kaj ; Akhøj, Morten ; Forman, Julie ; Hasselbalch, Steen Gregers ; Kessing, Lars Vedel. / Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. In: Journal of Affective Disorders. 2022 ; Vol. 297. pp. 623-633.

Bibtex

@article{68d6d07de9954ae8ae4d80a096af6f1b,
title = "Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study",
abstract = "Introduction: Bipolar disorder (BD) is a heterogeneous mental disorder characterized by recurrent relapses of affective episodes: Subgroups of patients with BD have cognitive deficits, and an increased risk of dementia. Methods: This prospective, longitudinal, one-year follow-up, case-control study investigated biomarkers for AD and neurodegenerative diseases, namely: cerebrospinal fluid (CSF) amyloid beta (Aβ) isoforms and ratios (Aβ42, Aβ40, Aβ38), CSF soluble amyloid precursor protein (sAPP) α and β, CSF total (t-tau) and phosphorylated tau (p-tau), CSF neurofilament-light (NF-L), CSF neurogranin (NG), plasma-isoforms Aβ42 and Aβ40, plasma-tau, plasma-NF-L, and serum S100B, in patients with BD (N = 62, aged 18–60) and gender-and-age-matched healthy control individuals (N = 40). CSF and plasma/serum samples were collected at baseline, during and after an affective episode, if it occurred, and after a year. Data were analyzed in mixed models. Results: Levels of CSF Aβ42 decreased in patients with BD who had an episode during follow-up (BD-E) (N = 22) compared to patients without an episode (BD-NE) (N = 25) during follow-up (P = 0.002). Stable levels were seen for all other markers in BD-E compared to BD-NE during the one-year follow-up. We found no statistically significant differences between patients with BD and HC at T0 and T3 for Aβ42, Aβ40, Aβ38, Aβ42/38, Aβ42/40, sAPPα, sAPPβ, t-tau, p-tau, p-tau /t-tau, NF-L, NG in CSF and further Aβ40, Aβ42, Aβ42/40, t-tau, NF-L in plasma, S100B in serum, and APOE-status. Furthermore, all 18 biomarkers were stable in HC during the one-year follow-up from T0 to T3. Conclusion: A panel of biomarkers of Alzheimer's and neurodegeneration show no differences between patients with BD and HC. There were abnormalities of amyloid production/clearance during an acute BD episode. The abnormalities mimic the pattern seen in AD namely decreasing CSF Aβ42 and may suggest an association with brain amyloidosis.",
keywords = "Amyloid, Bipolar disorder, Case-control, Cerebrospinal fluid, Longitudinal, Neurofilament light, Tau",
author = "Ulla Knorr and Simonsen, {Anja Hviid} and Jensen, {Camilla Steen} and Henrik Zetterberg and Kaj Blennow and Morten Akh{\o}j and Julie Forman and Hasselbalch, {Steen Gregers} and Kessing, {Lars Vedel}",
note = "Publisher Copyright: {\textcopyright} 2021",
year = "2022",
doi = "10.1016/j.jad.2021.10.074",
language = "English",
volume = "297",
pages = "623--633",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study

AU - Knorr, Ulla

AU - Simonsen, Anja Hviid

AU - Jensen, Camilla Steen

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Akhøj, Morten

AU - Forman, Julie

AU - Hasselbalch, Steen Gregers

AU - Kessing, Lars Vedel

N1 - Publisher Copyright: © 2021

PY - 2022

Y1 - 2022

N2 - Introduction: Bipolar disorder (BD) is a heterogeneous mental disorder characterized by recurrent relapses of affective episodes: Subgroups of patients with BD have cognitive deficits, and an increased risk of dementia. Methods: This prospective, longitudinal, one-year follow-up, case-control study investigated biomarkers for AD and neurodegenerative diseases, namely: cerebrospinal fluid (CSF) amyloid beta (Aβ) isoforms and ratios (Aβ42, Aβ40, Aβ38), CSF soluble amyloid precursor protein (sAPP) α and β, CSF total (t-tau) and phosphorylated tau (p-tau), CSF neurofilament-light (NF-L), CSF neurogranin (NG), plasma-isoforms Aβ42 and Aβ40, plasma-tau, plasma-NF-L, and serum S100B, in patients with BD (N = 62, aged 18–60) and gender-and-age-matched healthy control individuals (N = 40). CSF and plasma/serum samples were collected at baseline, during and after an affective episode, if it occurred, and after a year. Data were analyzed in mixed models. Results: Levels of CSF Aβ42 decreased in patients with BD who had an episode during follow-up (BD-E) (N = 22) compared to patients without an episode (BD-NE) (N = 25) during follow-up (P = 0.002). Stable levels were seen for all other markers in BD-E compared to BD-NE during the one-year follow-up. We found no statistically significant differences between patients with BD and HC at T0 and T3 for Aβ42, Aβ40, Aβ38, Aβ42/38, Aβ42/40, sAPPα, sAPPβ, t-tau, p-tau, p-tau /t-tau, NF-L, NG in CSF and further Aβ40, Aβ42, Aβ42/40, t-tau, NF-L in plasma, S100B in serum, and APOE-status. Furthermore, all 18 biomarkers were stable in HC during the one-year follow-up from T0 to T3. Conclusion: A panel of biomarkers of Alzheimer's and neurodegeneration show no differences between patients with BD and HC. There were abnormalities of amyloid production/clearance during an acute BD episode. The abnormalities mimic the pattern seen in AD namely decreasing CSF Aβ42 and may suggest an association with brain amyloidosis.

AB - Introduction: Bipolar disorder (BD) is a heterogeneous mental disorder characterized by recurrent relapses of affective episodes: Subgroups of patients with BD have cognitive deficits, and an increased risk of dementia. Methods: This prospective, longitudinal, one-year follow-up, case-control study investigated biomarkers for AD and neurodegenerative diseases, namely: cerebrospinal fluid (CSF) amyloid beta (Aβ) isoforms and ratios (Aβ42, Aβ40, Aβ38), CSF soluble amyloid precursor protein (sAPP) α and β, CSF total (t-tau) and phosphorylated tau (p-tau), CSF neurofilament-light (NF-L), CSF neurogranin (NG), plasma-isoforms Aβ42 and Aβ40, plasma-tau, plasma-NF-L, and serum S100B, in patients with BD (N = 62, aged 18–60) and gender-and-age-matched healthy control individuals (N = 40). CSF and plasma/serum samples were collected at baseline, during and after an affective episode, if it occurred, and after a year. Data were analyzed in mixed models. Results: Levels of CSF Aβ42 decreased in patients with BD who had an episode during follow-up (BD-E) (N = 22) compared to patients without an episode (BD-NE) (N = 25) during follow-up (P = 0.002). Stable levels were seen for all other markers in BD-E compared to BD-NE during the one-year follow-up. We found no statistically significant differences between patients with BD and HC at T0 and T3 for Aβ42, Aβ40, Aβ38, Aβ42/38, Aβ42/40, sAPPα, sAPPβ, t-tau, p-tau, p-tau /t-tau, NF-L, NG in CSF and further Aβ40, Aβ42, Aβ42/40, t-tau, NF-L in plasma, S100B in serum, and APOE-status. Furthermore, all 18 biomarkers were stable in HC during the one-year follow-up from T0 to T3. Conclusion: A panel of biomarkers of Alzheimer's and neurodegeneration show no differences between patients with BD and HC. There were abnormalities of amyloid production/clearance during an acute BD episode. The abnormalities mimic the pattern seen in AD namely decreasing CSF Aβ42 and may suggest an association with brain amyloidosis.

KW - Amyloid

KW - Bipolar disorder

KW - Case-control

KW - Cerebrospinal fluid

KW - Longitudinal

KW - Neurofilament light

KW - Tau

U2 - 10.1016/j.jad.2021.10.074

DO - 10.1016/j.jad.2021.10.074

M3 - Journal article

C2 - 34728295

AN - SCOPUS:85118530255

VL - 297

SP - 623

EP - 633

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -

ID: 286010185